Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Bioequivalence of 600mg dose of peramivir administered via intramuscular versus intravenous routes

Trial Profile

Bioequivalence of 600mg dose of peramivir administered via intramuscular versus intravenous routes

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 25 Nov 2014

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Peramivir (Primary) ; Peramivir (Primary)
  • Indications Influenza virus infections
  • Focus Pharmacokinetics
  • Sponsors BioCryst Pharmaceuticals
  • Most Recent Events

    • 20 Nov 2014 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top